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The hepatitis C virus and human immunodeﬁciency virus share the same transmission
routes,  which makes co-infection an unfavorable condition for the natural history of both
viral  diseases. In this context, it should be highlighted that the knowledge of the extent
of  co-infection and associated risk factors is a vital tool for prevention and control over
infectious  diseases. The aim of this study was to review the literature, seeking to examine
the  prevalence of human immunodeﬁciency virus/hepatitis C virus co-infection reported in
studies conducted in Brazil, and identify the main risk factors associated with co-infection.
The  electronic search was conducted in the Medline, Lilacs and SciELO databases. The
following  keywords were used: human immunodeﬁciency virus and Hepatitis C or hepatitis
C  virus and Brazil. The search led to 376 articles, of which 69 were selected for data extraction.
We  excluded animal studies, reports or case series, review articles, letters to the editor, other
types  of hepatitis and those studies in which co-infected patients were intentionally selected
for  comparison to single infected individuals. As a result, 40 articles were  reviewed. The
majority of the population in these studies was male (71%) and young adults, with a mean
age  of 26.7 years. The prevalence of hepatitis C virus co-infection among individuals living
with  human immunodeﬁciency virus in the studies conducted in Brazil ranged from 3.3%
(serum samples) to 82.4% (drug users), with an average of 20.3%. The ﬁndings reveal that
the prevalence of human immunodeﬁciency virus/hepatitis C virus co-infection is highlyvariable,  depending on the characteristics of the study population. Risk factors associated
with  human immunodeﬁciency virus/hepatitis C virus co-infection were injection drug use
and blood transfusion.
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HIV is most commonly spread by sexual contact with an
infected  partner, through contact with infected blood, acci-
dental  sticks or vertical transmission.2 HCV  transmission
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occurs mostly through infected blood and blood products, but
sexual, accidental and vertical transmission has been also
evidenced.3
The HIV/HCV co-infection is a signiﬁcant risk factor for
liver  ﬁbrosis, since HIV seropositivity and low CD4+ count
seems  to accelerate this process.4,5 The progression of ﬁbrosis
in  HCV/HIV co-infected patients occurs with high frequency
during  an average estimated time of three years.6 Similarly,
HCV  infection has been shown to be associated with faster
progression to acquired immunodeﬁciency syndrome (AIDS).7
In Brazil, according to the Epidemiological Bulletin on Viral
Hepatitis  (2011), co-infection rates reach a percentage of 11.4%
in  HIV-seropositive patients.8 This percentage shows regional
variation  being dependent on the characteristics of the study
population.  However, this estimate is based on cases reported
by  the Information System for Notiﬁable Diseases (SINAN),
and  may  not be representative of the general population, since
only  AIDS cases are reported, and there is a relative delay
between case detection and publishing of reports.8
Therefore, this study is intended to review this issue,
seeking to examine the prevalence of HIV/HCV co-infection
encountered in studies conducted in Brazil, and identify the
main  risk factors for this co-infection.
Methods
This is a narrative review on HIV/HCV co-infection in Brazil.
The  electronic search was  conducted in the Medline, Lilacs
and  SciELO databases. The following keywords were used: HIV
[MeSH] and HCV [textline] or Hepatitis C [MeSH] and Brazil
[textline] in English and the corresponding words in Por-
tuguese.  The references of the selected articles were examined
for  possible inclusion of additional articles.
We included original scientiﬁc articles that presented data
on  the prevalence of HIV/HCV co-infection in different popu-
lation  groups, of both sexes, conducted in Brazil.
We  excluded studies that addressed animal studies, reports
or  case series, review articles, letters to the editor, other
types  of hepatitis and those in which co-infected patients
were  intentionally selected for comparison to single-infected
patients.
Duplicate articles were excluded. We started reading the
titles,  then the abstracts, and later the full texts. Exclu-
sion  criteria were  applied in all stages, always by consensus
between two readers.
The  selected articles were analyzed to characterize the
study:  year of publication, location and period of data collec-
tion,  type of study, study population and sampling (number of
investigated  subjects, mean age and gender of participants),
prevalence rates of HIV, HCV and HIV/HCV co-infection, and
risk  factors associated with the presence of co-infection.
HIV-infected individuals were  considered those who had
positive  anti-HIV serology. HCV-infected individuals were
considered  those who  had positive anti-HCV serology. The co-
infection rates were  taken directly from the articles, and when
this  information was  not provided, they were  calculated by
dividing  the number of individuals who  had serological mark-
ers  for HIV and HCV by the total number of participants in the
study. 1 3;1  7(4):455–463
To calculate the mean age and the prevalence of HIV/HCV
co-infection, we used descriptive statistics to ﬁnd the
weighted mean, taking into account the sample size of each
study.
Results
The search led to 376 articles, of which 69 were selected
for  data extraction. After applying the exclusion criteria, 40
articles  remained (Fig. 1). This study period covered articles
published between April 1999 and June 2012.
Of the 40 articles analyzed, 36 were cross-sectional studies
(one  multisite), three cohort studies (two historical cohorts)
and  a descriptive study.
In  total, we studied 48,791 subjects; of these, 28,819 (59.0%)
were  pregnant women, 13,483 (27.6%) were  subjects or blood
samples  from HIV-infected patients, 2780 (5.7%) were  indi-
viduals  under restriction of freedom, 550 (1.1%) drug users,
3159  (6.6%) individuals with other characteristics, such as
alcoholics,  homeless people, garbage collectors, or patients
attending various outpatient clinics.
Demographic characteristics available in the selected stud-
ies  showed that the majority of participants were  men
(71%).9–34 Of the 40 selected articles, men  predominated in
the  samples of 26, with only one35 showing a predominance
of women. The samples of seven studies comprised only
women.35–41 The mean age was  26.7 years among the papers
that  presented this information.9–18,20–23,25,26,28,30–37,40–43 Eight
of the selected papers had no data regarding gender and age
of  the participants.38,39,44–49
In 20 articles,9–12,14–17,19–21,23,25,26,34,43–47 the study popula-
tion consisted entirely of HIV-infected individuals or serum
samples,  and showed HIV/HCV co-infection rates ranging
from  3.3%11 to 54.7%47 (Table 1), with an average of 19.5%.
Including the studies with pregnant women36,40 and injection
drug  users,29 whose participants were all infected with HIV as
well,  the weighted mean of HIV/HCV co-infection was  20.3%
among  13,894 participants.
Five  papers studied pregnant women, aiming to determine
the  prevalence of certain infectious diseases and/or verify
the  risk of vertical transmission.36–40 In these studies, the
prevalence of HIV/HCV co-infection ranged from 0.0000737 to
27.6%39 (Table 2).
Among drug users18,29,35 the prevalence of HIV/HCV co-
infection ranged from 15.1%35 to 82.4%29 (Table 3). Five studies
assessing individuals in restraint of freedom24,28,32,33,48 found
a  prevalence of co-infection ranging from 1.6%28 to 7.1%32
(Table 4).
The  HIV/HCV co-infection rates ranged from 0.6%30 among
homeless people who used hostels to 82.4%29 among injection
drug  users. Studies that have determined the prevalence of
HIV/HCV  co-infection in other populations are presented in
Table  5.
Out  of the 40 papers reviewed only 14 reported data
on  risk factors associated with HIV/HCV co-infection, and
these  highlighted the injection drug use as the main trans-
mission  mechanism,12,14,15,18,22,23,25,34,42,46 followed by blood
transfusion.9,17,23,25 Behavioral risks such as tattooing,11,23
piercing11 and exposure to infected blood,14 although to a
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Table 1 – Description of the studies on HIV/HCV co-infection among HIV-infected patients.
Reference,
year of
publication
Study  type and
sample size
Target population,
setting and study
period
Gender/sex, age
(mean ± SD)
Prevalence  of
HIV/HCV
co-infection
HIV/HCV
n (%)
Risk factor
associated with
HIV/HCV
co-infection
Carvalho FH et al.,
20099
Cross-sectional
n = 345
Individuals  living with HIV or
AIDS  attending the University
Hospital  of Recife (PE), from
March  to December 2003.
65% men 14 (4.1) Blood
transfusion
Corvino SM et al.,
200744
Cross-sectional
n = 150
HIV-infected patients
monitored  routinely at the
Tropical  Diseases and
Diagnostic  Imaging clinics, and
the  Hepato-Hemocentro of the
Faculty  of Medicine of
Botucatu.a
NA 22 (14.7) NA
Hadlich E et al.,
200710
Cross-sectional
n = 61
HIV  seropositive patients
treated  at a hospital in Porto
Alegre  (RS), between the year
2003  and September 2004.
59% men
38.0 ± 11.1 years
6 (10.0) NA
Santos EO et al.,
200811
Cross-sectional
n = 299
Blood  samples from HIV-
infected  patients treated at the
University Hospital of Maceió
(AL),  from May to November
2005.
65.6% men
40.0  years
10 (3.3) History of
hepatitis/icterus
and
tattooing/piercing
Mendes-Correa
MC et al., 200112
Cross-sectional
n = 1457
HIV-infected individuals
attending  the outpatient care
center  for patients with
HIV/AIDS  at the University of
São  Paulo (SP), from January to
December  1996.
82.2% men
34.08  ± 7.19 years
258 (17.7) Drug use and
sexual
transmission
Segurado AC
et  al., 200414
Cohort
n = 495
HIV-infected patients attending
the Santos AIDS Reference
Center,  in Santos (SP), from
February  1997 to January 1998.
55.4% men
35.7  years
179 (36.2) IDU and blood
exposure
Tovo CV et al.,
200615
Cross-sectional
n = 330
Medical  records of HIV-infected
patients  attending the
Infectious  Diseases Service,
Hospital  Nossa Senhora da
Conceic¸ão,  Porto Alegre (RS).a
62.4% men
34.4  ± 10.6 years
126 (38.2) IDU
Victoria MB et al.,
201016
Descriptive
n = 1582
AIDS  patients reported to
SINAN,  who underwent
serological  testing for hepatitis
C,  Tropical Medicine
Foundation of Amazonas,
between  2000 and 2007.
72.9% men
38.5  ± 10.2 years
70 (4.42) NA
Pavan MH, 200317 Cross-sectional
n = 221
Patients  living with HIV in the
city  of Campinas (SP), between
1992  and 1995.
69.4% men
30.8  years
119 (53.8) Blood
transfusion
Wolf FH et al.,
201045
Cross-sectional
n = 1143
HIV  patients under treatment
at  a referral outpatient center
for  HIV/AIDS of the Brazilian
public  health system, from
March  2005 to September 2006.
NA  357 (31.2) NA
Marins JR et al.,
200546
Historic cohort
n  = 2821
Adult  patients with AIDS in
Brazil  in 1995 and 1996. Data
collected  from medical records,
between  April 2000 and
January  2002.
NA 833 (29.5) IDU
Bonamigo RR
et  al., 200419
Cross-sectional
n = 105
HIV-infected patients with
dermatoses  treated at the
Dermatology  Clinic of the
Department  of Health of the
State  of Rio Grande do Sul.a
75.2% men 35 (38.0) NA
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Table 1 (Continued)
Reference,
year of
publication
Study  type and
sample size
Target population,
setting and study
period
Gender/sex, age
(mean ± SD)
Prevalence  of
HIV/HCV
co-infection
HIV/HCV
n (%)
Risk factor
associated with
HIV/HCV
co-infection
Carmo RA et al.,
200820
Historic cohort
n  = 824
HIV-infected patients treated at
the Reference Center for
Infectious  Diseases, Belo
Horizonte  (MG), from January
1996  to 30 June 2001.
64.3% men 76 (9.2) NA
Sampaio AS et al.,
200921
Cross-sectional
n = 429
HIV-infected patients treated at
the referral service to assist
people  with HIV infection at
the Oswaldo Cruz University
Hospital  of Recife (PE), between
July  and September 2004.
60.1% men
39.3  years
46 (10.7) NA
Mussi AD et al.,
200723
Cross-sectional
n = 1008
Individuals  living with HIV
treated  at the referral center of
Cuiabá  (MT), between January
2004  and July 2004.
51.5% men
37.2  years
110 (10.9) IDU, tattooing,
blood
transfusion
before 1991.
Treitinger A et al.,
199947
Cross-sectional
n = 95
Blood  samples from
HIV-positive  patients attending
the  Hospital Nereu Ramos or
Health Centre II, from April
1994  to March 1995.
NA 52 (54.7)
Monteiro MR
et  al., 200425
Cross-sectional
n = 406
Patients  living with HIV treated
at  the public health service in
the  city of Belém (PA), from
September  1999 to April 2000.
74.1% men
34.2  ± 8.26 years
65 (16.0) IDU, blood
transfusion or
blood  products,
and  age > 49
years.
Morimoto HK
et  al., 200526
Cross-sectional
n = 758
HIV-infected population
attending  various regional
centers  of the health referral
center  for AIDS in Paraná, from
September  2001 to December
2002.
55.9% men
36.7  ± 9.5 years
159  (21.0) NA
Braga EL et al.,
200627
Cross-sectional
n = 704
HIV  patients attending the
referral  centers in the state of
Amazonas, 2003.
65% men 35 (5.0) Use of illicit
drugs.
Santos KF et al.,
201034
Cross-sectional
n = 250
Medical  records of HIV-positive
patients  monitored at the
Clinic  of Infectious Diseases,
University  Hospital of Santa
Maria  (RS), from June to
November  2006.
76.9% men
33.8  ± 7.4 years
78  (31.2) IDU
iencyNA, not assessed; IDU, injection drug user; HIV, human immunodeﬁc
a Study period not reported.
lesser extent, as well as sexual exposure,12 homosexuality,18
and older age22,25 were  positively associated with the presence
of  HIV/HCV co-infection.
Discussion
This review comprised 40 studies that surveyed a total of
48,791  Brazilians, including pregnant women, subjects or
blood  samples from HIV-infected patients, individuals under
restriction  of freedom, drug users, individuals with other
characteristics, such as alcoholics, homeless people, garbage
collectors,  or patients attending various outpatient clinics.
Due  to this regional and population diversity, the prevalence
of  HIV/HCV co-infection had great amplitude. This variation virus; HCV, hepatitis C virus; SD, standard deviation; n, sample size.
is  explained by the exposure to different risk factors for co-
infection.2
Thus, we  chose to group the participants with similar char-
acteristics, creating subgroups to analyze the seroprevalence
rates of HIV/HCV co-infection.
Of  the 20 studies that had determined the prevalence of
HCV  co-infection among individuals living with HIV,  the aver-
age  co-infection rate was 19.5%, which is higher than the rate
of  11.8% published by the Ministry of Health in the last Epi-
demiological Bulletin of Viral Hepatitis.8 This can be attributed
to  the fact that this estimate is based on cases reported by the
SINAN,  and may  not be representative of the general popula-
tion,  since only AIDS cases are reported and there is a delay
between  case detection and publishing of reports.8
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What is the prevalence of HIV/HCV co-infection in adults in Brazil and which are the
risk factors associated with co-infection?
Keywords:      
4 articles excluded due to the
lack of data on HIV/HCV
co-infection
Identified articles–n=376
307 arti cles were remov ed (duplica tes and
other exclusion  crit eria)
Potential articles for
review
n= 69
31 articles excluded after
consensus meeting between
two readers:
1 HIV/HBV co-infection
1 letter to the editor
29 lack of data on HIV/HCV
co-infection
38 eligible articles + 6
after reviewing the
references
40 includ ed in the
review 
HIV
and
HCV or Hepatitis C
and
Brazil
Fig. 1 – Flowchart of the selection of articles.
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cThe HIV/HCV co-infection rates among individuals in
estraint  of freedom are higher than in the general popula-
ion.  Containment is considered a risk factor due to crowding
nto  small enclosures, promiscuity and rape, illicit drug use,
nd  sharing of personal hygiene objects. These factors cre-
te  favorable conditions for infection with HIV, HCV and
o-infection.50
According to the demographic characteristics of the par-
icipants  in the different studies, 71% were  men, which is in
ccordance  with the national and international data showing
hat  men  are the most affected group by HIV, HCV and, con-
equently,  co-infection.8,51,52 The mean age was  26.7 years,
.e.,  young adults, unlike some studies that showed older
ge  populations.7,15 This discrepancy can be explained by
he  inclusion of teenagers33 and pregnant women,36–40 e.g.,
omen  of childbearing age, and therefore, younger, coupled
ith  the fact that several studies did not provide the age of the
tudy  population,19,38,39,44–49 which may  have underestimated
his ﬁgure.19,38,39,44–49 It should be emphasized, however, that
he  predominance of men  and young population represents
he  sample described in the studies, and not the co-infection
ases, since these data were not available. Nevertheless, onecan  assume that there was  a demographic similarity among
the  detected co-infection cases.
The articles that addressed studies with pregnant women
showed  a great variation of co-infection rates, ranging
between 0.00007 and 27.6%.36–40 This variation can be
explained by the fact that only Costa et al.37 conducted
research with large numbers of pregnant women  to determine
the  prevalence of infection with HIV, HCV and co-infection,
reaching rate values of 0.13%, 0.22% and 0.00007%, respec-
tively.  These ﬁndings diverge from some different studies
included in the review, whose main objective was to ver-
ify  the vertical transmission by studying subgroups of HIV-
and  HCV-seropositive subjects or both, thereby increasing
the  rates found. In Brazil, the prevalence of HIV infection
in  pregnant women  is estimated to be 0.41%.53 There is no
national  estimate of the prevalence of HCV infection among
pregnant  women, but the rate of HCV vertical transmission is
0.3%.8
Injection drug use is a major mode of HIV and HCV
transmission.54 In all studies included in this review, injec-
tion  drug users had high rates of co-infection. This high
rate  of transmission can be attributed to the sharing of drug
460  b r a z j i n f e c t d i s . 2 0 1 3;1  7(4):455–463
Table 2 – Description of studies on HIV/HCV co-infection among pregnant women.
Reference, year
of  publication
Study  type and
sample size
Target  population, setting and
study  period
Age (mean ± SD) Prevalence
n  (%)
HIV HCV HIV/HCV
Tornatore M
et  al., 201236
Cross-sectional
n = 130
HIV-infected pregnant women
attending  the HIV/AIDS center at the
University Hospital of the Federal
University  of Rio Grande do Sul, from
July 2006 to December 2008.
26.2 ± 5.69 years 130 (100.0) 14 (10.8) 14 (10.8)
Costa ZB et al.,
200937
Cross-sectional
n = 28,561
Pregnant women attending antenatal
care  of the public health system in
Goiânia (GO), between 2004 and 2005.
23.9 ± 5.6 years 38 (0.13) 65 (0.22) 2 (0.00007)
Gardenal RV
et  al., 201138
Cross-sectional
n = 23
HCV-positive pregnant women
enrolled  in the System Information
Program  for Humanization of Prenatal
and  Birth (SISPRENATAL) used by the
Health Secretary of the municipality
of  Campo Grande (MS), between 2002
and 2005.
NA  2 (8.7) 23 (100.0) 2 (8.7)
Peixoto MF
et  al., 200439
Cross-sectional
n = 29
HCV-positive pregnant women
attending  antenatal care of the
Hospital  Nossa Senhora da Conceic¸ão
of  Porto Alegre (RS), from August 1998
to November 1999.
NA 8 (27.6) 29  (100.0) 8 (27.6)
Dal Fabbro MM
et  al., 200540
Cross-sectional
n = 76
HIV-infected pregnant women treated
at the Reference Department in
Campo  Grande (MS), from May 1996 to
October 2001.
24.0  years 76 (100.0) 11 (14.5) 11 (14.5)
is C vNA, not assessed; HIV, human immunodeﬁciency virus; HCV, hepatit
preparation equipment, facilitating HIV and HCV transmis-
sion  through the exposure to contaminated blood.55 This
pathway  is the main route of transmission for HCV. Drug injec-
tion  practices also predispose to other risky behaviors such
as  promiscuity, lack of condom use, homosexual intercourse,
among  others.56
Table 3 – Description of studies on HIV/HCV co-infection amon
Reference, year
of  publication
Study type and
sample size
Target population, setting and
study  period
Gen
(m
Zocratto KB,
200618
Cross-sectional
multisite study
n  = 272
Injecting drug users in 5
Brazilian  cities selected by the
AjUDE  Brasil-I project, starting
1998.
82.7%
29.25
von Diemen L
et  al., 201035
Cross-sectional
n = 73
Female crack users in Porto
Alegre  (RS), from August to
December  2004.
100%
28.1  
Marchesini AM
et  al., 200729
Cross-sectional
n = 205
Injection drug users infected
with  HIV under treatment at
the  STD/AIDS municipal health
department in São Paulo (SP),
from  January to November 2003.
81%  
39  ±
HIV, human immunodeﬁciency virus; HCV, hepatitis C virus; NA, not asses
STD, sexually transmitted diseases; AIDS, acquired immunodeﬁciency syn
a The HCV infection rate of 27.7% was calculated based on a sample of 65 irus; SD, standard deviation; n, sample size.
Different HIV/HCV co-infection rates were observed among
the  study population that participated in the studies included
in  this review. The heterogeneity of the studies did neither
allow  summarizing the prevalence of coinfection in each
subgroup  nor an overall prevalence. Therefore, we  opted to cal-
culate just the weighted average of HIV/HCV co-infection rate
g drug users.
der/sex, age
ean ± SD)
Prevalence
n  (%)
Risk factor
associated with
HIV/HCV
co-infectionHIV HCV HIV/HCV
 men
 ± 8.4 years
25 (9.2) 28 (10.3) 116 (42.6) IDU, male
homosexual
intercourse
 women
± 7.6 years
27 (37.0) 18 (27.7)a 11 (15.1) NA
men
 6.1 years
205 (100.0) 169 (82.4) 169 (82.4) NA
sed; SD, standard deviation; n, sample size; IDU, injection drug users;
drome.
participants who underwent anti-HCV testing.
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Table 4 – Description of studies on HIV/HCV co-infection among individuals in restraint of freedom.
Reference, year
of  publication
Study type and
sample size
Target population, setting and study
period
Gender/sex,
age
(mean ± SD)
Prevalence (%)
HIV HCV HIV/HCV
Pompilio MA
et  al., 201124
Cross-sectional
n = 686
Prisoners  of Mato Grosso do Sul State,
2009.
64.6% men 34 (5.0) 33 (4.8) 11 (1.6)
Gabe C and Lara
GM,  200848
Cross-sectional
n = 76
Serum  samples of female prison inmates
in Rio Grande do Sul, stored in the Santa
Helena Laboratory, Porto Alegre (RS).a
NA 7 (9.2) 11 (14.5) 2 (2.6)
Catalan-Soares
BC et al., 200028
Cross-sectional
n = 63
Prisoners  of Manhuac¸u  (MG).a 100% men
30.2  years
2  (3.2) 4  (6.3) 1  (1.6)
Guimaraes T
et  al., 200132
Cross-sectional
n = 756
Blood  samples of inmates at the House of
Detention in São Paulo (SP), between
December 1993 and January 1994.
100%  men
30.2  years
105  (13.7) 310 (41.0) 54 (7.1)
Zanetta DM
et  al., 199933
Cross-sectional
n = 1199
Teenagers  from two FEBEM centers in São
Paulo (SP), from December 1994 to April
1995.
92% men
16.2 years
38  (3.2) 21 (1.8) 21 (1.8)
HIV, human immunodeﬁciency virus; HCV, hepatitis C virus; NA, not assessed; SD, standard deviation; n, sample size; FEBEM, Portuguese
acronym for the State Foundation for the Well-Being of Minors.
a Study period not reported.
Table 5 – Description of studies on HIV/HCV co-infection among different population groups.
Reference, year
of  publication
Study  type and
sample size
Target population, setting and
study  period
Gender/sex,
age
(mean ± SD)
Prevalence (%) Risk factor
associated with
HIV/HCV
co-infectionHIV HCV HIV/HCV
Oliveira ML et al.,
200913
Cross-sectional
n = 131
Alcoholic  patients in a
consecutive  order, between
March  1998 and November
1999.
90.8%  men
44.3  ± 10.8
years
4 (3.0) 5 (4.2) 2 (1.5) NA
Pereira GA et al.,
200642
Cross-sectional
n = 592
People  attending a Center for
anonymous  testing and
counseling  for HIV in Goiânia
(GO).a
65% women 19 (3.2) 15 (2.5) 14 (2.4) IDU
Reis NR et al.,
201122
Cross-sectional
n = 402
Patients  under treatment for
tuberculosis  (TB) at the referral
hospital  for infectious diseases
in  Goiânia (GO), from April
2008  to March 2010.
71.9%  men
44.1  years
111 (27.6) 30 (7.5) 20 (5.0) Age, IDU and
HIV  infection
Portelinha Filho
AM  et al.,
200949
Cross-sectional
n = 1.228
Individuals  attending the Clinic
of Infectious Diseases at the Dr.
Dominic Leonardo Cerávolo
Regional  University Hospital in
Presidente  Prudente (SP), from
January  2000 to December 2006.
NA 303 (24.7) 173 (14.0) 49 (4.0) NA
Berra JAP et al.,
200641
Cross-sectional
n = 225
Serum  samples from patients
with  infectious diseases at the
Rio  Claro Regional Laboratory
of  the Adolfo Lutz Institute
(SP),  between March 2003 and
June 2004.
100%  women 8 (3.6) 17 (7.5) 2 (0.9) NA
Brito VO et al.,
200730
Cross-sectional
n = 330
Homeless  people who use
hostels  in Sao Paulo (SP), from
2002  to 2003.
80.9%  men
40.2  years
6 (1.8) 28 (8.5) 2 (0.6) NA
Rozman MA
et  al., 200831
Cross-sectional
n = 251
Seroepidemiological  survey of
autonomous  garbage collectors
in  the city of Santos (SP), June
2005.
84.9%  men
42.4  years
22 (8.9) 31 (12.4) 7 (2.8) NA
NA, not assessed; HIV, human immunodeﬁciency virus; HCV, hepatitis C virus; SD, standard deviation; n, sample size; IDU, injection drug user.
a Study period not reported.
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2462  b r a z j i n f e c t d 
in people living with HIV. The variation of coinfection rates
found  in this study is justiﬁed by the peculiar characteristics
of  the diverse population groups that are exposed to different
risk  factors.
The studies that reported data on risk factors asso-
ciated with HIV/HCV co-infection highlighted that
drug  injection practices were the main transmission
mechanism,12,14,15,18,22,23,25,34,46,57 followed by blood
transfusion.9,17,23,25 Since the risk factors for HIV and
HCV have close connection, these can be characterized as
behavioral  and biological factors.58
The limitations of this review include missing information
in  some articles that could allow a more  detailed analysis of
the  characteristics of the study populations and the risk fac-
tors  for co-infection.
Conclusion
The data show that the prevalence of HIV/HCV co-infection
is  highly variable, depending on the prevalence of HIV and
HCV  infection, and the exposure to various risk factors in the
study  populations. The prevalence of HIV/HCV co-infection
among people living with HIV was  20.3%. Risk factors asso-
ciated  with HIV/HCV co-infection were injection drug use and
blood  transfusion.
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